Concepts (200)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Sclerosis | 27 | 2024 | 329 | 5.160 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 11 | 2024 | 33 | 1.870 |
Why?
|
| Immunosuppressive Agents | 16 | 2024 | 649 | 0.950 |
Why?
|
| Meningoencephalitis | 1 | 2021 | 18 | 0.730 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 1 | 2021 | 18 | 0.730 |
Why?
|
| Meningitis, Cryptococcal | 1 | 2021 | 20 | 0.730 |
Why?
|
| JC Virus | 1 | 2021 | 30 | 0.720 |
Why?
|
| Cross Infection | 1 | 2024 | 323 | 0.710 |
Why?
|
| Fingolimod Hydrochloride | 5 | 2024 | 33 | 0.680 |
Why?
|
| Interferon-beta | 6 | 2011 | 52 | 0.660 |
Why?
|
| Recurrence | 6 | 2024 | 1421 | 0.610 |
Why?
|
| Glioblastoma | 1 | 2021 | 330 | 0.550 |
Why?
|
| Ganglioglioma | 1 | 2016 | 23 | 0.520 |
Why?
|
| Dimethyl Fumarate | 4 | 2024 | 11 | 0.510 |
Why?
|
| Brain Diseases | 2 | 2019 | 299 | 0.380 |
Why?
|
| Osteopontin | 1 | 2010 | 48 | 0.350 |
Why?
|
| Interleukin-17 | 1 | 2010 | 120 | 0.330 |
Why?
|
| Magnetic Resonance Imaging | 11 | 2021 | 3556 | 0.320 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 5 | 2021 | 1199 | 0.320 |
Why?
|
| Injections, Epidural | 1 | 2008 | 6 | 0.310 |
Why?
|
| Pneumocephalus | 1 | 2008 | 4 | 0.310 |
Why?
|
| Lateral Ventricles | 1 | 2008 | 14 | 0.310 |
Why?
|
| Adult | 26 | 2024 | 29489 | 0.310 |
Why?
|
| Dura Mater | 1 | 2008 | 25 | 0.310 |
Why?
|
| Young Adult | 9 | 2024 | 9025 | 0.300 |
Why?
|
| Sarcoidosis | 1 | 2008 | 60 | 0.290 |
Why?
|
| Headache | 1 | 2008 | 107 | 0.290 |
Why?
|
| Immunologic Factors | 5 | 2024 | 174 | 0.290 |
Why?
|
| Crotonates | 2 | 2024 | 6 | 0.280 |
Why?
|
| Middle Aged | 20 | 2024 | 26797 | 0.280 |
Why?
|
| Brain Neoplasms | 1 | 2016 | 1212 | 0.280 |
Why?
|
| Humans | 42 | 2024 | 124727 | 0.260 |
Why?
|
| Toluidines | 1 | 2024 | 3 | 0.230 |
Why?
|
| Hydroxybutyrates | 1 | 2024 | 44 | 0.230 |
Why?
|
| Myelin-Oligodendrocyte Glycoprotein | 1 | 2024 | 31 | 0.220 |
Why?
|
| Africa South of the Sahara | 1 | 2024 | 115 | 0.220 |
Why?
|
| Nitriles | 1 | 2024 | 146 | 0.210 |
Why?
|
| Female | 25 | 2024 | 66569 | 0.200 |
Why?
|
| Immunotherapy | 2 | 2024 | 673 | 0.200 |
Why?
|
| Adolescent | 13 | 2024 | 19288 | 0.200 |
Why?
|
| Brain | 6 | 2021 | 2982 | 0.200 |
Why?
|
| Medication Adherence | 2 | 2024 | 397 | 0.200 |
Why?
|
| Cost of Illness | 2 | 2020 | 249 | 0.200 |
Why?
|
| Male | 22 | 2024 | 61270 | 0.190 |
Why?
|
| Methotrexate | 3 | 2009 | 341 | 0.190 |
Why?
|
| Urinary Retention | 1 | 2021 | 18 | 0.190 |
Why?
|
| Central Nervous System Vascular Malformations | 1 | 2021 | 17 | 0.190 |
Why?
|
| Herpes Simplex | 1 | 2022 | 55 | 0.190 |
Why?
|
| Alemtuzumab | 2 | 2020 | 88 | 0.180 |
Why?
|
| Health Care Costs | 1 | 2024 | 371 | 0.180 |
Why?
|
| Adjuvants, Immunologic | 3 | 2009 | 381 | 0.180 |
Why?
|
| Health Expenditures | 2 | 2020 | 102 | 0.170 |
Why?
|
| Methylprednisolone | 3 | 2009 | 91 | 0.170 |
Why?
|
| Prescription Drugs | 1 | 2020 | 54 | 0.160 |
Why?
|
| Retrospective Studies | 11 | 2024 | 16334 | 0.160 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2020 | 111 | 0.150 |
Why?
|
| Cost-Benefit Analysis | 1 | 2020 | 509 | 0.140 |
Why?
|
| Aged, 80 and over | 2 | 2024 | 6548 | 0.140 |
Why?
|
| Pregnancy Outcome | 1 | 2020 | 588 | 0.140 |
Why?
|
| Antigens, CD34 | 1 | 2016 | 107 | 0.130 |
Why?
|
| Dendritic Cells | 2 | 2011 | 409 | 0.120 |
Why?
|
| Spinal Cord | 4 | 2021 | 300 | 0.120 |
Why?
|
| Treatment Outcome | 7 | 2021 | 12357 | 0.120 |
Why?
|
| Aged | 6 | 2024 | 19764 | 0.110 |
Why?
|
| Antibodies, Monoclonal | 2 | 2011 | 1018 | 0.110 |
Why?
|
| Longitudinal Studies | 3 | 2021 | 1328 | 0.100 |
Why?
|
| Quality of Life | 1 | 2022 | 1935 | 0.100 |
Why?
|
| Glucocorticoid-Induced TNFR-Related Protein | 1 | 2011 | 2 | 0.100 |
Why?
|
| Anti-Inflammatory Agents | 3 | 2009 | 287 | 0.100 |
Why?
|
| Down-Regulation | 2 | 2011 | 699 | 0.090 |
Why?
|
| Autoantibodies | 2 | 2024 | 434 | 0.090 |
Why?
|
| Electroencephalography | 1 | 2016 | 864 | 0.090 |
Why?
|
| Lymphocyte Activation | 2 | 2011 | 691 | 0.090 |
Why?
|
| Infant, Newborn | 1 | 2024 | 8191 | 0.090 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2011 | 49 | 0.090 |
Why?
|
| Administration, Oral | 2 | 2024 | 680 | 0.090 |
Why?
|
| Nerve Tissue Proteins | 1 | 2016 | 1111 | 0.090 |
Why?
|
| Infant | 2 | 2024 | 12475 | 0.080 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2011 | 217 | 0.080 |
Why?
|
| Child, Preschool | 2 | 2024 | 14017 | 0.080 |
Why?
|
| Linear Models | 2 | 2022 | 676 | 0.080 |
Why?
|
| Up-Regulation | 1 | 2011 | 862 | 0.080 |
Why?
|
| Bupivacaine | 1 | 2008 | 24 | 0.080 |
Why?
|
| Glatiramer Acetate | 3 | 2022 | 11 | 0.080 |
Why?
|
| Atrophy | 3 | 2021 | 228 | 0.080 |
Why?
|
| Low Back Pain | 1 | 2008 | 37 | 0.080 |
Why?
|
| Follow-Up Studies | 3 | 2024 | 5161 | 0.080 |
Why?
|
| Neuromyelitis Optica | 1 | 2008 | 31 | 0.070 |
Why?
|
| Transplantation, Autologous | 3 | 2017 | 298 | 0.070 |
Why?
|
| Child | 3 | 2024 | 24385 | 0.070 |
Why?
|
| Prednisone | 1 | 2008 | 275 | 0.070 |
Why?
|
| Biopsy | 2 | 2008 | 1237 | 0.070 |
Why?
|
| Steroids | 1 | 2008 | 202 | 0.070 |
Why?
|
| Antibodies, Neoplasm | 1 | 2007 | 60 | 0.070 |
Why?
|
| Encephalitis, Viral | 1 | 2007 | 20 | 0.070 |
Why?
|
| Meningioma | 1 | 2008 | 120 | 0.070 |
Why?
|
| Roseolovirus Infections | 1 | 2007 | 33 | 0.070 |
Why?
|
| Interferon beta-1a | 4 | 2009 | 18 | 0.070 |
Why?
|
| Disability Evaluation | 3 | 2017 | 193 | 0.070 |
Why?
|
| Herpesvirus 6, Human | 1 | 2007 | 58 | 0.070 |
Why?
|
| Meningeal Neoplasms | 1 | 2008 | 185 | 0.070 |
Why?
|
| Logistic Models | 2 | 2022 | 1812 | 0.060 |
Why?
|
| United States | 4 | 2024 | 10899 | 0.060 |
Why?
|
| Acute Disease | 1 | 2008 | 1110 | 0.060 |
Why?
|
| Drugs, Investigational | 1 | 2005 | 22 | 0.060 |
Why?
|
| Multiple Sclerosis, Chronic Progressive | 1 | 2004 | 9 | 0.060 |
Why?
|
| Financing, Personal | 1 | 2004 | 10 | 0.060 |
Why?
|
| Demyelinating Autoimmune Diseases, CNS | 1 | 2024 | 7 | 0.060 |
Why?
|
| Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 1 | 2004 | 14 | 0.060 |
Why?
|
| Myelin Basic Protein | 1 | 2004 | 67 | 0.060 |
Why?
|
| Disease-Free Survival | 2 | 2017 | 873 | 0.050 |
Why?
|
| Image Enhancement | 1 | 2005 | 163 | 0.050 |
Why?
|
| Autoantigens | 1 | 2004 | 118 | 0.050 |
Why?
|
| Epitopes | 1 | 2005 | 432 | 0.050 |
Why?
|
| Diagnosis, Differential | 1 | 2008 | 1883 | 0.050 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2004 | 235 | 0.050 |
Why?
|
| Peptides | 2 | 2004 | 795 | 0.050 |
Why?
|
| Genetic Markers | 1 | 2004 | 604 | 0.050 |
Why?
|
| Monocytes | 1 | 2004 | 351 | 0.050 |
Why?
|
| Interferon Type I | 1 | 2002 | 107 | 0.050 |
Why?
|
| Stem Cell Transplantation | 1 | 2004 | 230 | 0.050 |
Why?
|
| Paraparesis | 1 | 2021 | 10 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2021 | 4804 | 0.050 |
Why?
|
| Cross-Sectional Studies | 2 | 2020 | 3432 | 0.050 |
Why?
|
| Sex Factors | 1 | 2024 | 1287 | 0.040 |
Why?
|
| Constipation | 1 | 2021 | 115 | 0.040 |
Why?
|
| Injections | 1 | 2021 | 154 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2008 | 2092 | 0.040 |
Why?
|
| Models, Economic | 1 | 2020 | 51 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2005 | 1090 | 0.040 |
Why?
|
| Activities of Daily Living | 1 | 2022 | 402 | 0.040 |
Why?
|
| Office Visits | 1 | 2020 | 77 | 0.040 |
Why?
|
| Epidemiologic Methods | 1 | 2019 | 110 | 0.040 |
Why?
|
| Abortion, Spontaneous | 1 | 2020 | 79 | 0.040 |
Why?
|
| Health Care Surveys | 1 | 2020 | 287 | 0.040 |
Why?
|
| Lactation | 1 | 2020 | 192 | 0.040 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2019 | 142 | 0.040 |
Why?
|
| T-Lymphocytes | 2 | 2004 | 1707 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2021 | 1259 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2004 | 1701 | 0.030 |
Why?
|
| Data Interpretation, Statistical | 2 | 2009 | 231 | 0.030 |
Why?
|
| Cells, Cultured | 3 | 2011 | 3038 | 0.030 |
Why?
|
| Cooperative Behavior | 2 | 2009 | 218 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2020 | 1189 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2024 | 3447 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2011 | 505 | 0.030 |
Why?
|
| Drug Therapy, Combination | 2 | 2009 | 1163 | 0.030 |
Why?
|
| Patient Selection | 2 | 2009 | 695 | 0.030 |
Why?
|
| Disease Progression | 2 | 2015 | 2049 | 0.030 |
Why?
|
| Risk Factors | 2 | 2024 | 10286 | 0.030 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2020 | 729 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2020 | 723 | 0.030 |
Why?
|
| Algorithms | 1 | 2019 | 1622 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2022 | 3716 | 0.020 |
Why?
|
| Clonal Anergy | 1 | 2011 | 5 | 0.020 |
Why?
|
| Natalizumab | 1 | 2011 | 3 | 0.020 |
Why?
|
| Hospitalization | 1 | 2020 | 1779 | 0.020 |
Why?
|
| CTLA-4 Antigen | 1 | 2011 | 53 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2004 | 681 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2004 | 1284 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2015 | 1233 | 0.020 |
Why?
|
| Antibodies, Antiphospholipid | 1 | 2008 | 19 | 0.020 |
Why?
|
| Pregnancy | 1 | 2020 | 7178 | 0.020 |
Why?
|
| Autopsy | 1 | 2007 | 111 | 0.020 |
Why?
|
| Cerebrospinal Fluid Proteins | 1 | 2007 | 23 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2007 | 337 | 0.020 |
Why?
|
| Glucocorticoids | 1 | 2008 | 381 | 0.020 |
Why?
|
| DNA, Viral | 1 | 2007 | 480 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2008 | 777 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2007 | 662 | 0.020 |
Why?
|
| Transplantation Conditioning | 1 | 2007 | 324 | 0.010 |
Why?
|
| Chad | 1 | 2004 | 1 | 0.010 |
Why?
|
| Axons | 1 | 2007 | 377 | 0.010 |
Why?
|
| Interleukin-1 | 1 | 2004 | 142 | 0.010 |
Why?
|
| Genes, Immunoglobulin | 1 | 2004 | 33 | 0.010 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2004 | 52 | 0.010 |
Why?
|
| Lymphocyte Count | 1 | 2004 | 116 | 0.010 |
Why?
|
| Income | 1 | 2004 | 133 | 0.010 |
Why?
|
| Thymus Gland | 1 | 2004 | 101 | 0.010 |
Why?
|
| Hematologic Neoplasms | 1 | 2007 | 284 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2011 | 3717 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 2004 | 330 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 2050 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2007 | 1586 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2004 | 325 | 0.010 |
Why?
|
| Interleukin-10 | 1 | 2004 | 172 | 0.010 |
Why?
|
| Data Collection | 1 | 2004 | 381 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2011 | 4376 | 0.010 |
Why?
|
| Cell Division | 1 | 2004 | 777 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2004 | 502 | 0.010 |
Why?
|
| Poverty | 1 | 2004 | 422 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2004 | 1016 | 0.010 |
Why?
|
| Killer Cells, Natural | 1 | 2002 | 327 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2002 | 1390 | 0.010 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2002 | 482 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2004 | 1883 | 0.010 |
Why?
|
| Cytokines | 1 | 2002 | 1290 | 0.010 |
Why?
|
| Animals | 2 | 2011 | 34027 | 0.010 |
Why?
|
| Mice | 1 | 2011 | 17578 | 0.010 |
Why?
|
| Time Factors | 1 | 2004 | 6308 | 0.010 |
Why?
|